March 21 (Bloomberg) -- Nasvax Ltd. rose the most in almost three months after its parent company Biomedix Incubator Ltd. said Nasvax’s Phase 2a clinical trial of a treatment for fatty liver was successful.
Nasvax shares climbed as much as 8.9 percent, the biggest intraday gain since Dec. 27, to 1.63 shekels. They traded 2.3 percent higher at 1.53 shekels as of 11:24 a.m. in Tel Aviv. Biomedix increased 3.6 percent to 0.607 shekel.
To contact the reporter on this story: Ronit Goodman in Tel Aviv at email@example.com
To contact the editor responsible for this story: Claudia Maedler at firstname.lastname@example.org